In the BioHarmony Drug Report Database

"Preview" Icon

Cemiplimab-rwlc

Libtayo (cemiplimab) is an antibody pharmaceutical. Cemiplimab was first approved as Libtayo on 2018-09-28. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat squamous cell carcinoma. The pharmaceutical is active against programmed cell death protein 1.

 

Trade Name

 

Libtayo
 

Common Name

 

cemiplimab
 

ChEMBL ID

 

CHEMBL4297723
 

Indication

 

squamous cell carcinoma
 

Drug Class

 

Monoclonal antibodies: immunomodulating

Image (chem structure or protein)

Cemiplimab-rwlc structure rendering